Aug 10, 2024
NEW ALZHEIMER’S BLOOD TEST
What is Alzheimer’s Disease?
Alzheimer’s disease (AD) is a progressive neurological disorder that causes brain cells to degenerate and die, leading to a continuous decline in cognitive function. This disease is the most common cause of dementia—a continuous decline in thinking, behavioral, and social skills that disrupts a person’s ability to function independently.
What are the traditional methods for diagnosing Alzheimer’s?
Traditionally, Alzheimer’s diagnosis involves a combination of medical history assessment, neurological exams, mental status tests, and brain imaging. Techniques like MRI scans, CT scans, and more invasively, cerebrospinal fluid analysis through lumbar puncture, and amyloid or Tau Positron Emission Tomography (PET) scans are used to look for markers of the disease.
What is the new Alzheimer’s blood test?
The new Alzheimer’s blood test, known as PrecivityAD2, detects Alzheimer’s disease by analyzing blood for specific biomarkers associated with AD. These biomarkers include plasma phosphorylated-tau217 and amyloid-beta proteins (AB42 and AB40). This test has shown about 90% accuracy in diagnosing Alzheimer’s, particularly in its early stages, offering a significant improvement over some traditional methods.
How does this test improve treatment?
By enabling an earlier and more accurate diagnosis, the test allows for the timely initiation of treatment plans that can slow the progression of Alzheimer’s when it is most manageable. Early intervention is key to preserving cognitive function and quality of life for as long as possible.
Is it more affordable?
Yes, the test is more cost-effective than many traditional diagnostic methods like PET scans, which are expensive and less accessible. Being a simple blood test, it reduces the need for more invasive, uncomfortable, and costly diagnostic procedures.
Will it be available in India soon?
While the test shows promise, its availability in India will depend on regulatory approvals and commercial availability. Dr. E.S. Krishnamoorthy noted that while current diagnostic tools in India include MRI and regular PET scans, the specific amyloid or Tau PET scans used for AD are not yet commercially available. The introduction of the blood test in India is anticipated, but it may initially be accessible only at specialized centers or for those who can afford it, even at a reduced cost.
Future Implications
Further studies and evaluations are needed to determine how this test could be integrated into routine clinical care and its overall impact on healthcare costs and patient outcomes in Alzheimer’s disease management.
SRIRAM's
